SHKK(SH:600272)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥224,420,347.32, representing a 40.55% increase compared to ¥159,676,507.71 in the same period last year[6]. - The net profit attributable to shareholders for Q3 2023 decreased by 35.81% to ¥2,866,790.29 from ¥4,492,877.66 in the previous year[6]. - The basic earnings per share for Q3 2023 was ¥0.011, down 38.89% from ¥0.018 in the same period last year[6]. - Total revenue for the first three quarters of 2023 was ¥615,115,410.65, a decrease of 11.7% compared to ¥696,448,928.07 in the same period of 2022[18]. - Operating profit for the first three quarters of 2023 was ¥28,515,998.48, down 53.4% from ¥61,265,047.61 in the first three quarters of 2022[18]. - Net profit for the first three quarters of 2023 was ¥18,500,205.24, a decline of 47.0% compared to ¥34,907,309.11 in the same period of 2022[18]. - Basic earnings per share for the first three quarters of 2023 was ¥0.081, down from ¥0.137 in the same period of 2022[18]. Cash Flow - The company reported a net cash flow from operating activities of -¥42,172,918.53 for the year-to-date period[6]. - Cash flow from operating activities for the first three quarters of 2023 was negative at -¥42,172,918.53, an improvement from -¥148,290,581.25 in the same period of 2022[21]. - Cash flow from investing activities for the first three quarters of 2023 was negative at -¥73,295,592.27, compared to a positive cash flow of ¥15,358,622.46 in the same period of 2022[21]. - Cash and cash equivalents at the end of the first three quarters of 2023 amounted to ¥117,836,402.16, an increase from ¥68,718,269.62 at the end of the same period in 2022[21]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,210,402,408.49, a decrease of 2.23% from the previous year's end[6]. - As of September 30, 2023, the company's total assets amounted to CNY 1,183,430,033.30, a decrease from CNY 1,210,402,408.49 at the end of 2022, reflecting a decline of approximately 2.0%[14]. - The company's current assets totaled CNY 578,877,364.14, down from CNY 589,293,001.32, indicating a decrease of about 1.4%[14]. - The company's total liabilities decreased from CNY 632,056,029.32 to CNY 598,733,448.89, reflecting a decline of about 5.3%[15]. - Total current liabilities decreased from CNY 435,213,299.44 to CNY 409,186,584.81, a reduction of approximately 6.0%[15]. Changes in Financial Metrics - The weighted average return on equity for Q3 2023 was 0.51%, down 0.29 percentage points from 0.80% in the previous year[6]. - Non-recurring gains and losses for Q3 2023 totaled ¥1,641,906.60, compared to ¥10,262,699.91 for the year-to-date period[7]. - The company experienced a significant decrease in net profit due to the absence of compensation income from property acquisition in the current period[8]. - Financial expenses decreased by 1,063.53% due to changes in exchange gains and losses compared to the previous year[9]. Inventory and Receivables - Trade receivables increased by 58.24% due to a rise in sales volume to certain credit customers[9]. - Prepayments increased by 262.48% due to higher procurement in the pharmaceutical sector settled through prepayment[9]. - The company's inventory decreased slightly from CNY 88,718,754.49 to CNY 86,716,621.06, a decline of about 2.3%[14]. - The company reported a significant increase in accounts payable from CNY 209,334,956.57 to CNY 246,716,488.59, representing an increase of about 17.9%[15]. Other Income and Investments - Other income increased by 96.42% due to higher government subsidies received compared to the previous year[9]. - Investment income increased by 1,144.55% due to higher long-term equity investment income recognized under the equity method[9]. - The company recorded an investment income of ¥2,141,871.24 in the first three quarters of 2023, significantly up from ¥172,099.67 in the same period of 2022[18].